Sujay Kango
Vorstandsvorsitzender bei Tmunity Therapeutics, Inc.
Vermögen: - $ am 31.01.2024
Profil
Sujay R.
Kango currently works at Tmunity Therapeutics, Inc., as President & Chief Executive Officer.
Mr. Kango also formerly worked at MEI Pharma, Inc., as Independent Director from 2021 to 2023, Infinity Pharmaceuticals, Inc., as Independent Director from 2022 to 2023, Cancer Care, Inc., as Director, Merck & Co., Inc., as Vice President-Hepatitis Franchise from 2006 to 2011, Schering-Plough Corp., as Head-Sales & Marketing, Onyx Pharmaceuticals, Inc., as VP-Global Marketing & Sales Operations from 2011 to 2015, Acceleron Pharma, Inc., as Chief Commercial Officer & Senior Vice President, AbbVie, Inc., as Vice President-Oncology Global Commercial from 2017 to 2018, and Infinity Pharmaceuticals, Inc., as Chief Commercial Officer & Executive VP from 2015 to 2017.
Mr. Kango received his undergraduate degree and Masters Business Admin degree from McNeese State University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 30.05.2023 | 0 ( -.--% ) | - $ | 31.01.2024 |
Aktive Positionen von Sujay Kango
| Unternehmen | Position | Beginn |
|---|---|---|
Tmunity Therapeutics, Inc.
 Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Sujay Kango
| Unternehmen | Position | Ende |
|---|---|---|
| MEI PHARMA, INC. | Direktor/Vorstandsmitglied | 31.10.2023 |
| INFINITY PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 24.07.2023 |
| ABBVIE INC. | Corporate Officer/Principal | 01.02.2018 |
| INFINITY PHARMACEUTICALS, INC. | Corporate Officer/Principal | 06.01.2017 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Vertrieb & Marketing | 01.03.2015 |
Ausbildung von Sujay Kango
| McNeese State University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| MERCK & CO., INC. | Health Technology |
| ABBVIE INC. | Health Technology |
| MEI PHARMA, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Cancer Care, Inc.
 Cancer Care, Inc. Hospital/Nursing ManagementHealth Services Cancer Care, Inc. provides cancer treatment services. The firm's services include counseling and support groups, education, financial assistance and practical help. The company was founded in 1944 and is headquartered in New York, NY. | Health Services |
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis on June 13, 2003 and is headquartered in Rahway, NJ. | Health Technology |
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | Commercial Services |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
